Results 91 to 100 of about 2,458 (200)
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
Cancer Science, Volume 116, Issue 8, Page 2189-2197, August 2025.CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara +15 more
wiley +1 more source
Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape [PDF]
, 2019 Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in developed countries. CLL is diagnosed with absolute B lymphocyte count (B-ALC) >5000/micrL sustained for at least 3 months, morphologically mature-appearing small lymphocytes, and ...
Khan, Cyrus +2 more
core +2 more sources
The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study
Oral Diseases, Volume 31, Issue 8, Page 2641-2651, August 2025.ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah +4 more
wiley +1 more source
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
CA: A Cancer Journal for Clinicians, Volume 75, Issue 4, Page 282-307, July/August 2025.Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari +7 more
wiley +1 more source
International Journal of Analytical ChemistryDuvelisib (COPIKTRA, Pfizer) is a prescription medication indicated for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two previous treatments that were ineffective or have ceased to be ...
Mohamed W. Attwa +3 more
doaj +1 more source
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas [PDF]
, 2019 INTRODUCTION: Copanlisib is a phosphoinositol 3-kinase (PI3K) inhibitor approved for the third-line treatment of follicular non-Hodgkin lymphoma. Although the drug is generally well-tolerated, it can be associated with several unique and potentially ...
Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M
core +1 more source
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
Mediterranean Journal of Hematology and Infectious Diseases, 2016 Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions with a median ...
Giuseppe Rossi, Antonella Anastasia
doaj +1 more source
Research progress in targeted therapies of chronic lymphocytic leukemia
Shanghai Jiaotong Daxue xuebao. Yixue banChronic lymphocytic leukemia (CLL) is one of small B-cell lymphomas and leukemias, characterized as a clonal disease of mature B cells. The disease is remarkably heterogeneous, with the majority of patients having an indolent course, yet they are ...
DING Yanling, LI Jie, YUAN Jun, LI Yan
doaj +1 more source
Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities [PDF]
Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are approved by the US Food and Drug Administration (FDA) for cancer and noncancer indications.
Geffert, Raeanne M +2 more
core +2 more sources